ClinicalTrials.gg
RecruitingNCT07695207Updated Jul 10, 2026

Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy

A Phase 3 interventional study of SMZ1 and SMZ1 Placebo in Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy, sponsored by SANGMYUNG innovation. Recruiting at 1 site in South Korea. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by SANGMYUNG innovation · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Sep 2025, registered Jun 2026).
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Macular Degeneration with a site in Korea, Republic of — 11 open to participants now, 13 under way, 5 of them phase 3. Macular Degeneration · Korea, Republic of.

Planned enrollment
19th of 56
266 · median 81
Started
2025
with 6 others
Phase 3
22 of 67
4 open now
Primary completion
2027-12
later than 6 of 12 live
Registered
65th of 67
by date

Among the 67 studies in Macular Degeneration with a site in Korea, Republic of, this one is the 19th largest by planned enrollment of the 56 interventional ones that give a count, is one of 7 that started in 2025, is one of 22 in phase 3, reaches primary completion later than 6 of the 12 other live ones, and was the 65th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

11 of the 67 studies in Macular Degeneration with a site in Korea, Republic of are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Macular Degeneration with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of SMZ1 tablets in combination with Ranibizumab compared with placebo in combination with Ranibizumab in subjects with neovascular (wet) age-related macular degeneration (nAMD) without polypoidal choroidal vasculopathy (PCV). The primary objective is to demonstrate the superiority of SMZ1 tablets over placebo with respect to improvement in best-corrected visual acuity at Month 12.

03

Conditions studied

  • Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy

Keywords

  • SMZ1-301
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 50 years of age or older
  • A study eye satisfying all of the following criteria after screening

    ① Active* submacular choroidal neovascularization due to nAMD confirmed by fluorescein angiography (FAG) and optical coherence tomography (OCT)

    *Fluorescence leakage confirmed via FAG and intraretinal or subretinal fluid confirmed via OCT

    ② Absence of active polypoidal lesions due to polypoidal choroidal vasculopathy (PCV) confirmed by indocyanine green angiography (ICGA)

  • A study eye with fibrosis covering less than 50% of the total lesion area
  • A study eye with ETDRS best corrected visual acuity (BCVA) score range of 73-24 at a distance of 4m (equivalent to 20/40-20/320 of Snellen)
  • A study eye with a neovascular lesion area of less than 12 optic-disk areas (For an optic nerve head diameter set to 1.8mm, the corresponding optic-disk area is 2.45mm2)
  • Provided written voluntarily after receiving a full explanation of the clinical trial.

Exclusion criteria

Exclusion Criteria:

  • History of ocular treatment, systemic therapies, or surgical procedures, such as photodynamic therapy (PDT) and laser photocoagulation, for the treatment of wet nAMD (supplements and vitamins excluded)
  • History of anti-VEGF treatment (e.g., ranibizumab, bevacizumab, aflibercept 2mg, or biosimilars) or combination therapy in the study eye for the treatment of wet nAMD
  • A study eye with scarring or fibrosis covering more than 50% of the total lesion area
  • A study eye with vitreous hemorrhage occurring within 1 month prior to the Screening Visit
  • A study eye with intraocular pressure (IOP) ≥ 25mmHg, including glaucoma with IOP ≥ 25mmHg despite medical treatment
  • A study eye with a total lesion area (including vessels, scar tissue, and neovascularization) greater than 12 optic-disk areas (>30.5mm2), as measured by FAG
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
266 participants (estimated)

Study arms

  • Experimental
    SMZ1 Group

    SMZ1 + Ranibizumab

    Drug: SMZ1

  • Placebo comparator
    SMZ1 Placebo Group

    SMZ1 Placebo + Ranibizumab

    Drug: SMZ1 Placebo

Interventions

  • DrugSMZ1

    * Loading Phase (3 months): SMZ1 BID and Ranibizumab Monthly injection; * PRN Phase (9 months): SMZ1 BID and Ranibizumab PRN injection

  • DrugSMZ1 Placebo

    * Loading Phase (3 months): SMZ1 Placebo BID and Ranibizumab monthly injection; * PRN Phase (9 months): SMZ1 Placebo BID and Ranibizumab PRN injection

06

What researchers measure

Primary outcomes

  1. Best corrected visual acuity (BCVA) at Month 12

    Change in BCVA score from baseline, at Month 12 after the administration of the investigational drug using early treatment diabetic retinopathy study (ETDRS) chart

    Time frame: Month 12

Secondary outcomes

  1. Monthly BCVA

    Change in BCVA score from baseline, at each month after the administration of the investigational drug for 11 months (excluding Month 12) using ETDRS chart

    Time frame: Monthly for 11 months

  2. Central retinal thickness (CRT) every three months

    Change in CRT from the screening visit, at Month 3, 6, and 12 after the administration of the investigational drug measured with optical coherence tomography (OCT)

    Time frame: Month 3, 6, and 12

  3. Ranibizumab retreatment

    Number of Ranibizumab retreatment through Month 4 and 12, following the Ranibizumab loading phase of 3 months

    Time frame: Through Month 4 and 12

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 27 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 10, 2026
StartActual
Sep 15, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Jul 2028
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07695207
Lead sponsor
SANGMYUNG innovation
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Sep 15, 2025
Primary completion
Dec 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jul 10, 2026

Study contacts

Nahyun Kang, Ph.D
Contact
nahyun.kang@sminnovation.com
+82 2-3489-6298

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion